News

Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Explore the latest advancements in psoriasis treatment, including pediatric care and innovative therapies, during Psoriasis Action Month. Stay informed!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

In case you missed it, this week we had news about a novel PDE4 inhibitor for plaque psoriasis, the evolution of 5-ALA, a new melanoma treatment plan combining vidutolimod with pembrolizumab, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.

Robert Koppel, MD, led Case-Based Roundtable attendees through 3 complex cases of atopic dermatitis that centered around available non-steroidal topicals and biologics.

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

Discover the promising results of ME3183, a novel oral treatment for plaque psoriasis, showing significant efficacy and safety in a recent study.

BioMendics initiates TAMES-02 trial for TolaSure, a groundbreaking therapy targeting the root cause of Epidermolysis Bullosa Simplex, offering new hope.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.

The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.

Patients receiving BoNT-A plus topical cream reported greater satisfaction and better skin lightness than with cream alone.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the complexities of medication sampling, balancing patient access with ethical and safety concerns in clinical practice.

Discover how Rolf-Markus Szeimies, MD, is revolutionizing at-home skin care with 5-ALA, enhancing cellular health and hydration in daily routines.

Parents advocate for children with chronic skin conditions, highlighting school challenges and the need for better support in pediatric dermatology.

This review of the latest dermatologic studies includes a review of photoprotection in patients with skin of color, the presence of inflammatory cytokines in acne patients after isotretinoin treatment, perceptions of skin-lightening products in medical students, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.

Unlock exclusive insights from Elevate-Derm Summer 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips.

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.